SecProbe.io

Filing text and metadata
Intelligence Terminal Search Topics Monthly Activity About

Correspondence 0000950170-25-000095 from Aptevo Therapeutics Inc. (APVO)

Aptevo Therapeutics Inc.
Date: Jan. 2, 2025 · CIK: 0001671584 · Accession: 0000950170-25-000095

AI Filing Summary & Sentiment

Sentiment
Urgency
Document Type
Confidence
SEC Posture
Company Posture

Summary

Reasoning

File numbers found in text: 333-283983

Date
December 31, 2024
Author
Daphne Taylor
Form
CORRESP
Company
Aptevo Therapeutics Inc.

Letter

VIA EDGAR United States Securities and Exchange Commission Division of Corporation Finance Office of Life Sciences Washington, D.C. 20549 Attention: Mr. Chris Edwards Re: Aptevo Therapeutics Inc. Registration Statement on Form S-3 File No. 333-283983

Dear Mr. Edwards:

In accordance with Rule 461 under the Securities Act of 1933, as amended, we hereby request acceleration of the effective date of the Registration Statement on Form S-3 (File No. 333-283983) of Aptevo Therapeutics Inc. (the “Registration Statement”). We respectfully request that the Registration Statement become effective as of 4:15 p.m., Eastern Time, on January 2, 2025, or as soon as practicable thereafter. Once the Registration Statement has been declared effective, please confirm that event with our counsel, Paul Hastings LLP, by calling Sean M. Donahue at (202) 551-1704.

Very truly yours,
Aptevo Therapeutics Inc.

Show Raw Text
CORRESP
1
filename1.htm

  CORRESP

  December 31, 2024

  VIA EDGAR

  United States Securities and Exchange Commission

  Division of Corporation Finance

  Office of Life Sciences

  100 F Street, N.E.

  Washington, D.C. 20549

  Attention: Mr. Chris Edwards

  Re: Aptevo Therapeutics Inc.

  Registration Statement on Form S-3
File No. 333-283983

  Dear Mr. Edwards:

  In accordance with Rule 461 under the Securities Act of 1933, as amended, we hereby request acceleration of the effective date of the Registration Statement on Form S-3 (File No. 333-283983) of Aptevo Therapeutics Inc. (the “Registration Statement”). We respectfully request that the Registration Statement become effective as of 4:15 p.m., Eastern Time, on January 2, 2025, or as soon as practicable thereafter. Once the Registration Statement has been declared effective, please confirm that event with our counsel, Paul Hastings LLP, by calling Sean M. Donahue at (202) 551-1704.

  Very truly yours,

  Aptevo Therapeutics Inc.

  By: /s/ Daphne Taylor

  Daphne Taylor

  SVP & Chief Financial Officer

    CC:

    SoYoung Kwon, Aptevo Therapeutics Inc.
Sean M. Donahue, Paul Hastings LLP